RIYADH, Saudi Arabia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre said it will open Saudi Arabia's first facility for manufacturing genetic and cellular therapies by late 2025, a project designed to give thousands of patients access to advanced treatments at home, reduce the cost of care by an estimated eight billion riyals — about two billion dollars — by 2030, and meet roughly nine percent of the nation's demand for such therapies.
The new plant, located on the hospital's Riyadh campus, will produce CAR T-cell and stem-cell therapies, treatments that re-engineer a patient's own cells to fight cancer or repair damaged tissue. Spanning more than 5,000 square meters, the facility is designed around 16 modular clean-room clusters that can expand or adapt as new therapeutic technologies evolve.
Officials said the complex marks a milestone in Saudi Arabia's biotechnology ambitions, bringing precision medicine and advanced manufacturing together. Once fully operational, it is expected to manufacture about 2,400 treatment doses each year, advancing the country's capacity to produce some of the world's most sophisticated therapies.
The facility will operate under Good Manufacturing Practice standards, the global framework that governs pharmaceutical production. Each process, from air filtration to batch testing, will be monitored to ensure sterility, safety, and consistency. Artificial-intelligence systems will manage quality control, while the modular layout allows rapid scaling as innovation grows.
KFSHRC already has experience in the field. More than 200 patients have received CAR T-cell therapy there since 2020, years before local manufacturing began. The new site builds on that clinical record while advancing a broader research and training ecosystem aimed at preparing Saudi scientists and attracting global experts in gene and cell therapy. Officials said the goal is to make the kingdom not only a center for treatment but also for drug discovery and manufacturing.
At this year's Global Health Exhibition 2025 in Riyadh, the hospital is showcasing the new manufacturing complex alongside its advances in robotic surgery, genetic diagnostics, and augmented-reality medical training. The presentation highlights how the country's flagship hospital is aligning with broader national efforts to shift from healthcare consumption to healthcare creation.
KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world's top 250 academic medical centers for 2025. It was also recognized by Brand Finance 2025 as the most valuable healthcare brand in the Middle East and listed in Newsweek's World's Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its position as a global leader in innovation-driven patient care.
For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9ee13e5-9172-4352-8980-34db6df55b50
-
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi ArabiaRIYADH, Saudi Arabia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre said it will open Saudi Arabia's first fac2025-10-27
-
红色铸魂守清廉,瑞众保险广东分公司河源中支开展党建共建活动近日,瑞众保险广东分公司河源中支与中国邮政集团有限公司广东省龙川县分公司携手走进河源龙川福建会馆,以“红色教育+清廉建设”为主题开展党建共建活动,进一2025-10-27
-
关爱罕见病,瑞众保险广东分公司为每一个生命全力以赴瓷娃娃、黏宝宝、月亮孩子……这些不是动画片里的卡通人物,而是一个个罕见病群体的“名字”。其中“渐冻症”(肌萎缩侧索硬化症)因尚无完全治愈的方法,又被称为2025-10-27
-
微云全息(NASDAQ: HOLO)预计2025年全年净利润将超过3.5亿元人民币深圳2025年10月27日 美通社 -- 微云全息公司(纳斯达克:HOLO)(以下简称为“HOLO”或“公司”),一家技术服务提供商,预计2025年全年将实现显著的盈利能力,并实现同比大幅增长2025-10-27
-
传承红色廉风,筑牢廉洁防线,瑞众保险广东分公司汕尾中支开展清廉教育活动近日,瑞众保险广东分公司汕尾中支党支部组织党员干部赴汕尾市澎湃故居廉政教育基地开展沉浸式学习活动, 厚植清廉文化根基,强化党员干部廉洁从业意识。2025-10-27
